Cancer risks among patients with type 2 diabetes: a 10-year follow-up study of a nationwide population-based cohort in Taiwan

BMC Cancer

Cheng-Chieh Lin¹  Jen-Huai Chiang⁵  Chia-Ing Li¹  Chiu-Shong Liu²  Wen-Yuan Lin²  Teng-Fu Hsieh⁴  Tsai-Chung Li³ 

[1] Department of Medical Research, China Medical University Hospital, Taichung, Taiwan

[2] School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan

[3] Department of Healthcare Administration, College of Health Science, Asia University, Taichung, Taiwan

[4] Graduate Institute of Clinical Medical Science, College of Medicine, China Medical University, Taichung, Taiwan

[5] Health Promotion Administration, Ministry of Health and Welfare, Taipei, Taiwan

关键词: Breast cancer;    Pancreas cancer;    Colorectal cancer;    Liver cancer;    Cancer risks;    T2DM;   

Others  :  858775
DOI  :  10.1186/1471-2407-14-381

 received in 2013-10-31, accepted in 2014-05-20,  发布年份 2014

【 摘 要 】

Background

This study aims to determine cancer risks among patients with type 2 diabetes through a follow-up study on a nationwide population-based cohort that included Taiwanese diabetic patients and general population in Taiwan as well as to estimate the population attributable fraction (PAF) of site-specific cancer risks that can be attributed to type 2 diabetes in Taiwanese population by using standardized incidence ratios (SIRs, 95% CI).

Methods

Subjects with type 2 diabetes consisted of 472,979 patients aged ≥20 years, whereas general population consisted of 9,411,249 individuals of the same age limit but are not diabetic. Subjects were identified from 1997 to 1998 and followed up until December 31, 2007 or until the first manifestation of any cancer.

Results

Cancer sites with increased risks in men, which were consistent with the main and sensitivity analyses, included pancreas (SIR = 1.62; 95% CI = 1.53 to 1.72), liver (1.61; 1.57 to 1.64), kidney (1.32; 1.25 to 1.40), oral (1.16, 1.12 to 1.21), and colorectal (1.19, 1.15 to 1.22). Cancer sites with increased risks in women included liver (1.55; 1.51 to 1.60), pancreas (1.44; 1.34 to 1.55), kidney (1.38; 1.30 to 1.46), endometrium (1.36; 1.26 to 1.47), bladder (1.19; 1.11 to 1.27), colorectal (1.16; 1.13 to 1.20), and breast (1.14; 1.09 to 1.18). Overall, PAFs were highest for liver cancer in men (4.0%) and women (3.7%), followed by pancreas (3.4%) and kidney (1.6%) cancers in men, and then for endometrium (1.8%) and kidney (1.8%) cancers in women.

Conclusion

Our data suggested that increased cancer risks are associated with type 2 diabetes.

【 授权许可】

   
2014 Lin et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]World Health Organization (WHO): The World Health Report 2004: Changing History. 2004. Available: http://www.who.int/whr/2004/en/ webcite
• [2]Lin CC, Li CI, Hsiao CY, Liu CS, Yang SY, Lee CC, Li TC: Time trend analysis of the prevalence and incidence of diagnosed type 2 diabetes among adults in Taiwan from 2000 to 2007: a population-based study. BMC Public Health 2013, 13:318. BioMed Central Full Text
• [3]Chang CH, Shau WY, Jiang YD, Li HY, Chang TJ, Sheu WH, Kwok CF, Ho LT, Chuang LM: T2DM prevalence and incidence among adults in Taiwan during 1999–2004: a national health insurance data set study. Diabet Med 2010, 27:636-643.
• [4]Health Promotion Administration, Ministry of Health and WelfareAvailable: http://www.hpa.gov.tw/BHPNet/Web/HealthTopic/TopicArticle.aspx?id=201102140001&parentid=200712250011 webcite
• [5]Limburg PJ, Vierkant RA, Fredericksen ZS, Leibson CL, Rizza RA, Gupta AK, Ahlquist DA, Melton LJ 3rd, Sellers TA, Cerhan JR: Clinically confirmed T2DM mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol 2006, 101:1872-1879.
• [6]Hemminki K, Li X, Sundquist J, Sundquist K: Risk of cancer following hospitalization for T2DM. Oncologist 2010, 15:548-555.
• [7]El-Serag HB, Tran T, Everhart JE: Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-468.
• [8]Fujino Y, Mizoue T, Tokui N, Yoshimura T: Prospective study of diabetes mellitus and liver cancer in Japan. Diabetes Metab Res Rev 2001, 17:374-379.
• [9]Wang J, Webb G, Cao Y, Steiner DF: Contrasting patterns of expression of transcription factors in pancreatic alpha and beta cells. Proc Natl Acad Sci U S A 2003, 100:12660-12665.
• [10]Gullo L, Pezzilli R, Morselli-Labate AM, Italian Pancreatic Cancer Study Group: Diabetes and the risk of pancreatic cancer. N Engl J Med 1994, 331:81-84.
• [11]Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA, Manson JE: Nurses’ health study. T2DM and subsequent incidence of breast cancer in the Nurses’ health study. Diabetes Care 2003, 26:1752-1758.
• [12]Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA: Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 2009, 169:937-945.
• [13]Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL: Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009, 137:482-488.
• [14]World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR): Food, Nutrition and the Prevention of Cancer: A Global Perspective. Washington DC: WCRF/AICR; 1997.
• [15]Schienkiewitz A, Schulze MB, Hoffmann K, Kroke A, Boeing H: Body mass index history and risk of T2DM : results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr 2006, 84:427-433.
• [16]Considine RV, Premkumar A, Reynolds JC, Sebring NG, Ricks M, Sumner AE: Adiponectin and leptin in African Americans. Obesity (Silver Spring) 2008, 16:428-434.
• [17]Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D: Diabetes and cancer: a consensus report. CA Cancer J Clin 2010, 60:207-221.
• [18]Ren X, Zhang X, Zhang X, Gu W, Chen K, Le Y, Lai M, Zhu Y: T2DM mellitus associated with increased risk for colorectal cancer: evidence from an international ecological study and population-based risk analysis in China. Public Health 2009, 123:540-544.
• [19]Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, Borch-Johnsen K, Olsen JH: Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997, 89:1360-1365.
• [20]Tseng CH: Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care 2011, 34:616-621.
• [21]Huang YC, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, Chang SC, Lan YT, Wang HS, Liu CY, Yang YW, Teng HW: Diabetes mellitus negatively impacts survival of patients with colon cancer, particularly in stage II disease. J Cancer Res Clin Oncol 2011, 137:211-220.
• [22]Chen HF, Chen P, Li CY: Risk of malignant neoplasms of liver and biliary tract in diabetic patients with different age and sex stratifications. Hepatology (Baltimore, Md) 2010, 52:155-163.
• [23]Tseng CH, Chong CK, Tai TY: Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006. Diabetologia 2009, 52:240-246.
• [24]Lu JF, Hsiao WC: Does Universal health insurance make health care unaffordable? Lessons from Taiwan. Health Aff (Millwood) 2003, 22:77-88.
• [25]Liu CY, Hung YT, Chuang YL, Chen YJ, Weng WS, Liu JS, Liang KY: Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manag 2006, 4:1-22.
• [26]Rockhill B, Newman B, Weinberg C: Use and misuse of population attributable fractions. Am J Public Health 1998, 88(1):15-19.
• [27]Stephansson O, Granath F, Ekbom A, Michels KB: Risk of breast cancer among daughters of mothers with diabetes: a population-based cohort study. Breast Cancer Res 2010, 12:R14. BioMed Central Full Text
• [28]Lam EK, Batty GD, Huxley RR, Martiniuk AL, Barzi F, Lam TH, Lawes CM, Giles GG, Welborn T, Ueshima H, Tamakoshi A, Woo J, Kim HC, Fang X, Czernichow S, Woodward M, Asia Pacific Cohort Studies Collaboration: Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region. Ann Oncol 2011, 22(3):730-738.
• [29]Balkau B, Kahn HS, Courbon D, Eschwège E, Ducimetière P, Paris Prospective Study: Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: the Paris Prospective Study. Diabetes Care 2001, 24:843-849.
• [30]Rousseau MC, Parent ME, Pollak MN, Siemiatycki J: Diabetes mellitus and cancer risk in a population-based case–control study among men from Montreal, Canada. Int J Cancer 2006, 118:2105-2109.
• [31]Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ: Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004, 159:1160-1167.
• [32]Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM: Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005, 293:194-202.
• [33]Michaud DS, Liu S, Giovannucci E, Willett WC, Colditz GA, Fuchs CS: Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study. J Natl Cancer Inst 2002, 94:1293-1300.
• [34]Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM: Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005, 129:504-511.
• [35]Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE: Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005, 161:147-152.
• [36]Coker AL, Sanderson M, Zheng W, Fadden MK: Diabetes mellitus and prostate cancer risk among older men: population-based case–control study. Br J Cancer 2004, 90:2171-2175.
• [37]Bonovas S, Filioussi K, Tsantes A: Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004, 47:1071-1078.
• [38]Gonzalez-Perez A, Garcia Rodriguez LA: Prostate cancer risk among men with diabetes mellitus (Spain). Cancer Causes Control 2005, 16:1055-1058.
• [39]Tavani A, Gallus S, Bertuzzi M, Dal Maso L, Zucchetto A, Negri E, Franceschi S, Ramazzotti V, Montella M, La Vecchia C: Diabetes mellitus and the risk of prostate cancer in Italy. Eur Urol 2005, 47:313-317.
• [40]Batty GD, Shipley MJ, Marmot M, Smith GD: Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: findings from the original Whitehall study. Cancer Causes Control 2004, 15:873-881.
• [41]Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO: Diabetes mellitus and ovarian cancer (Sweden). Cancer Causes Control 2002, 13:759-764.
• [42]Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M: Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.
• [43]Coffey DS: Physiological control of prostatic growth: an overview. In: Prostate Cancer. Geneva Switzerland: Int Union Against Cancer 1979, 48:4-23.
• [44]Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996, 88:1118-1126.
• [45]Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L: Low levels of sex hormone–binding globulin and testosterone predict the development of non–insulin-dependent diabetes mellitus in men: Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996, 143:889-897.
• [46]Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, Gardenal R, Dal Mas M, Casarin P, Zanette G, Miranda C: Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009, 15:2506-2511.